Christophe Arbet-Engels, MD, Q1: Empagliflozin Studies Results

Dr. Christophe Arbet-Engels, discusses some of the study results on empagliflozin in which more than 14,000 patients were involved in several different study configurations including monotherapy, empagliflozin as an add-on, and patients with renal impairment.  

Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

See more SGLT-2 Resources